March 09, 2026

Side Effects: The Details Hiding in Plain Sight

Phones in class, a 25-year prescription gone wrong, pickleball's hidden danger, and why your spin class is too loud — four findings hiding in everyday care.

Conexiant

March 06, 2026

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo

Conexiant

March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

February 27, 2026

Children With OSA Face Higher Influenza, COVID-19 Risk

Real-world analysis finds higher risk of influenza and COVID-19 diagnoses over five years, with no evidence of reduced risk after adenotonsillectomy

Conexiant

February 26, 2026

How Sleep Disruption Affects Male Fertility 

Review links insomnia, sleep apnea, and circadian disruption to impaired spermatogenesis.

Conexiant

February 25, 2026

Sleep Apnea’s Billion-Dollar Toll

New analysis links untreated OSA to major productivity losses in working-age adults in the US and UK

Conexiant

February 23, 2026

Sleep Disruption and Osteoarthritis Risk

Investigators find that short sleep, insomnia, and night shift work are associated with increased risk of knee and hip osteoarthritis and joint replacement.

Conexiant

February 19, 2026

Quality of Life in Cardiac Arrest Recovery

Post–cardiac arrest care is increasingly structured around survivorship, with standardized patient-reported assessments supporting multidisciplinary follow-up.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 17, 2026

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Conexiant